GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
03 2021
Historique:
received: 09 10 2020
accepted: 26 01 2021
entrez: 13 3 2021
pubmed: 14 3 2021
medline: 19 4 2022
Statut: epublish

Résumé

Glucose-dependent insulinotropic polypeptide (GIP) communicates nutrient intake from the gut to islets, enabling optimal levels of insulin secretion via the GIP receptor (GIPR) on β cells. The GIPR is also expressed in α cells, and GIP stimulates glucagon secretion; however, the role of this action in the postprandial state is unknown. Here, we demonstrate that GIP potentiates amino acid-stimulated glucagon secretion, documenting a similar nutrient-dependent action to that described in β cells. Moreover, we demonstrate that GIP activity in α cells contributes to insulin secretion by invoking paracrine α to β cell communication. Last, specific loss of GIPR activity in α cells prevents glucagon secretion in response to a meal stimulus, limiting insulin secretion and driving glucose intolerance. Together, these data uncover an important axis by which GIPR activity in α cells is necessary to coordinate the optimal level of both glucagon and insulin secretion to maintain postprandial homeostasis.

Identifiants

pubmed: 33712466
pii: 7/11/eabf1948
doi: 10.1126/sciadv.abf1948
pmc: PMC7954443
pii:
doi:

Substances chimiques

Incretins 0
Receptors, G-Protein-Coupled 0
Receptors, Gastrointestinal Hormone 0
Gastric Inhibitory Polypeptide 59392-49-3
Glucagon 9007-92-5
gastric inhibitory polypeptide receptor D6H00MV7K8
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK113103
Pays : United States
Organisme : NIDDK NIH HHS
ID : F32 DK116542
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG062328
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK127637
Pays : United States
Organisme : NIDDK NIH HHS
ID : F32 DK121420
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007012
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK125353
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK101991
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK123075
Pays : United States

Informations de copyright

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Références

Diabetes. 2009 Jun;58(6):1342-9
pubmed: 19276444
J Diabetes Investig. 2016 Apr;7 Suppl 1:50-5
pubmed: 27186356
Regul Pept. 1991 Feb 1;32(2):65-73
pubmed: 2034823
JCI Insight. 2019 Mar 7;4(5):
pubmed: 30720465
J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13
pubmed: 12788877
Diabetes. 2013 Apr;62(4):1196-205
pubmed: 23160527
Mol Metab. 2016 May 03;5(7):449-458
pubmed: 27408771
J Clin Endocrinol Metab. 1993 Apr;76(4):912-7
pubmed: 8473405
Nat Rev Drug Discov. 2020 Apr;19(4):277-289
pubmed: 31848464
Cell Metab. 2017 Jun 6;25(6):1362-1373.e5
pubmed: 28591638
JCI Insight. 2019 Jul 23;5:
pubmed: 31335319
Peptides. 2020 Mar;125:170213
pubmed: 31785304
J Clin Invest. 1993 Jan;91(1):301-7
pubmed: 8423228
Nat Med. 2016 Jan;22(1):84-90
pubmed: 26642437
Cell Metab. 2018 Mar 6;27(3):549-558.e4
pubmed: 29514065
Lancet Diabetes Endocrinol. 2016 Jun;4(6):525-36
pubmed: 26876794
Metabolism. 2019 Jul;96:46-55
pubmed: 31029770
Endocrinology. 2020 Nov 1;161(11):
pubmed: 32964214
Am J Physiol Endocrinol Metab. 2011 Jun;300(6):E1038-46
pubmed: 21386059
Diabetes. 1996 Feb;45(2):257-61
pubmed: 8549871
Biochem Pharmacol. 2017 May 1;131:78-88
pubmed: 28237651
JCI Insight. 2019 Apr 23;5:
pubmed: 31012868
Cell Metab. 2017 Apr 4;25(4):927-934.e3
pubmed: 28325479
Diabetes. 2019 May;68(5):906-917
pubmed: 30626611
Lancet. 1965 Aug 28;2(7409):415-6
pubmed: 14346763
Cell Metab. 2014 Jun 3;19(6):1050-7
pubmed: 24836562
Cell Metab. 2019 Nov 5;30(5):976-986.e3
pubmed: 31495689
J Biol Chem. 2020 Aug 14;295(33):11529-11541
pubmed: 32554468
Cell Rep. 2018 Oct 30;25(5):1127-1134.e2
pubmed: 30380405
Biochem Biophys Res Commun. 2010 Jul 23;398(2):260-5
pubmed: 20599729
Neuron. 2015 Mar 4;85(5):942-58
pubmed: 25741722
Cell Metab. 2013 Jun 4;17(6):819-837
pubmed: 23684623
Mol Metab. 2017 Jan 12;6(3):236-244
pubmed: 28271030
Am J Physiol Endocrinol Metab. 2020 Jun 1;318(6):E920-E929
pubmed: 32255678
Diabetes. 2011 Dec;60(12):3103-9
pubmed: 21984584
Cell Rep. 2018 Jan 2;22(1):255-268
pubmed: 29298426
Diabetologia. 2003 Jun;46(6):798-801
pubmed: 12764578
J Clin Endocrinol Metab. 2014 Jul;99(7):2477-85
pubmed: 24712564

Auteurs

K El (K)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.

S M Gray (SM)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.

M E Capozzi (ME)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.

E R Knuth (ER)

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.

E Jin (E)

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.

B Svendsen (B)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.

A Clifford (A)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.

J L Brown (JL)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.

S E Encisco (SE)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.

B M Chazotte (BM)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.

K W Sloop (KW)

Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

D J Nunez (DJ)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.

M J Merrins (MJ)

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.

D A D'Alessio (DA)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.
Division of Endocrinology, Department of Medicine, Duke University, Durham, NC, USA.

J E Campbell (JE)

Duke Molecular Physiology Institute, Duke University, Durham, NC, USA. jonathan.campbell@duke.edu.
Division of Endocrinology, Department of Medicine, Duke University, Durham, NC, USA.
Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH